EXAGEN INC (XGN) Stock Price, Forecast & Analysis
USA - NASDAQ:XGN - US30068X1037 - Common Stock
XGN Key Statistics, Chart & Performance
The current stock price of XGN is 11.83 USD. In the past month the price increased by 8.53%. In the past year, price increased by 315.09%.
XGN Latest News, Press Relases and Analysis
XGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.43 | 374.44B | ||
| AMGN | AMGEN INC | 13.59 | 159.52B | ||
| GILD | GILEAD SCIENCES INC | 14.9 | 151.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.15 | 109.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.27 | 68.07B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.12 | 56.90B | ||
| ARGX | ARGENX SE - ADR | 61.62 | 50.87B | ||
| INSM | INSMED INC | N/A | 39.36B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.03 | 34.25B | ||
| NTRA | NATERA INC | N/A | 27.21B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.99B | ||
| BIIB | BIOGEN INC | 9.05 | 22.20B |
Related stock screener links
About XGN
Company Profile
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 203 full-time employees. The company went IPO on 2019-09-19. The firm is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Company Info
EXAGEN INC
1261 Liberty Way
Vista CALIFORNIA 92081 US
CEO: Fortunato Ron Rocca
Employees: 212
Phone: 17605601501
EXAGEN INC / XGN FAQ
Can you describe the business of EXAGEN INC?
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 203 full-time employees. The company went IPO on 2019-09-19. The firm is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
What is the stock price of EXAGEN INC today?
The current stock price of XGN is 11.83 USD. The price increased by 1.37% in the last trading session.
What is the dividend status of EXAGEN INC?
XGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of XGN stock?
XGN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is EXAGEN INC (XGN) stock traded?
XGN stock is listed on the Nasdaq exchange.
Should I buy XGN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on XGN.
How many employees does EXAGEN INC have?
EXAGEN INC (XGN) currently has 212 employees.
XGN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to XGN. When comparing the yearly performance of all stocks, XGN is one of the better performing stocks in the market, outperforming 98.25% of all stocks.
XGN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XGN. Both the profitability and financial health of XGN have multiple concerns.
XGN Financial Highlights
Over the last trailing twelve months XGN reported a non-GAAP Earnings per Share(EPS) of -0.86. The EPS increased by 11.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.9% | ||
| ROE | -80.73% | ||
| Debt/Equity | 1.06 |
XGN Forecast & Estimates
12 analysts have analysed XGN and the average price target is 13.41 USD. This implies a price increase of 13.32% is expected in the next year compared to the current price of 11.83.
For the next year, analysts expect an EPS growth of 18.32% and a revenue growth 21.08% for XGN